Cystic fibrosis (CF) results from the dysfunction of the cystic fibrosis transmembrane conductance regulatory (CFTR) protein, which affects both bicarbonate and chloride transport. Although most commonly associated with lung disease, CF also is associated with diabetes. Cystic fibrosis–related diabetes (CFRD) now affects up to 50 percent of adult patients and is associated with significant increased mortality. The mechanisms by which CFTR dysfunction contributes to diabetes remain poorly defined.
The CFRD Scientific Workshop, sponsored by the CF Foundation and NIDDK, is an online webinar to be held June 23–25, 2021. Multiple aspects of CFRD will be discussed, such as the mechanisms of disease, including the sites of CFTR function and the interaction between the exocrine and endocrine pancreas. In addition, prevention and treatment of CFRD and the effect of CFTR modulator therapy on glucose and insulin will be discussed.
The workshop goals are to share basic and clinical research data that highlight our understanding of CFRD disease mechanisms and treatment and to identify key research questions and knowledge gaps that will inform research priorities and potentially help NIDDK and/or the CF Foundation frame future funding opportunities.
June 25, 2021
June 23, 2021
- 10:00 a.m. – 10:10 a.m.
J. P. Clancy
MECHANISMS OF DISEASE
Moderators: Andi Kelly, Michael Rickels
- 10:10 a.m. – 10:30 a.m.
- Incretins, Exocrine Pancreas
- 10:30 a.m. – 10:50 a.m.
- Enteroinsular Axis in Cystic Fibrosis (CF)
- 10:50 a.m. – 11:10 a.m.
- Exocrine Pancreas Disease and Diabetes
- 11:10 a.m. – 11:30 a.m.
- Islet Vascularization and Inflammation in CF
- 11:30 a.m. – 11:45 a.m.
- 11:45 a.m. – 12:05 p.m.
- Innervation of the CF Pancreas
- 12:05 p.m. – 12:25 p.m.
- Cystic Fibrosis–Related Diabetes (CFRD) Genetics
- 12:25 p.m. – 12:45 p.m.
- Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), Islets, and Insulin Secretion
- 12:45 p.m. – 1:05 p.m.
- Role of Insulin Resistance (CF Post-CFTR Modulators)
- 1:05 p.m. – 1:35 p.m.
- General Discussion with Summary Knowledge Gaps
- 1:35 p.m. – 2:15 p.m.
- CFRD from a Parent’s/Patient’s Perspective
Meagan Helmick and Sharon Cray
June 24, 2021
PREVENTION AND TREATMENT, PART 1
Moderator: Melissa Putman and George Gittes
- 10:00 a.m. – 10:20 a.m.
- Glycemic Abnormalities in Young Children
Katie Larson Ode
- 10:20 a.m. – 10:40 a.m.
- Pancreatic Progenitors and Disease Remodeling
- 10:40 a.m. – 11:00 a.m.
- Developmental Aspects of CFRD: How Early Are CFTR Modulators Needed?
- 11:00 a.m. – 11:20 a.m.
- CFTR Modulators and the Exocrine Pancreas and Bile Acids
- 11:20 a.m. – 11:35 a.m.
- 11:35 a.m. – 11:55 a.m.
- CFTR Modulators: Impact upon Glucose and Insulin Secretion
- 11:55 a.m. – 12:15 p.m.
- Nutritional Impact upon Glycemia and Insulin Secretion
- 12:15 p.m. – 12:35 p.m.
- Anabolic Effects of Insulin, Needed before Diabetes?
- 12:35 p.m. – 12:55 p.m.
- Defining Glycemic Targets in CFRD Management
- 12:55 p.m. – 1:15 p.m.
- Artificial Pancreas Technology for CFRD
- 1:15 p.m. – 2:00 p.m.
- General Discussion with Summary of Knowledge Gaps
June 25, 2021
PREVENTION AND TREATMENT, PART 2
Moderator: Tanicia Daley Andy Norris
- 9:00 a.m. – 9:20 a.m.
- Preventing CFRD: The Role of Redox Imbalance
- 9:20 a.m. – 9:40 a.m.
- Microvascular Complications in Type 1 Diabetes: How Do These Apply to CF?
- 9:40 a.m. – 10:00 a.m.
- Clinical Future of CFRD: 10-Year View
- 10:00 a.m. – 10:50 a.m.
- Panel Discussion of Knowledge Gaps
- 10:50 a.m. – 11:00 a.m.
- Closing Remarks
- 11:00 a.m.